Zura Bio (NASDAQ:ZURA) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Zura Bio (NASDAQ:ZURA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09, Zacks reports. The company had revenue of $0.00 million during the quarter.

Zura Bio Stock Performance

Shares of ZURA traded up $0.03 during midday trading on Monday, hitting $1.30. 168,733 shares of the company traded hands, compared to its average volume of 376,592. Zura Bio has a 52 week low of $1.07 and a 52 week high of $6.35. The firm has a 50 day moving average of $1.46 and a 200-day moving average of $2.72. The stock has a market cap of $84.56 million, a price-to-earnings ratio of -2.46 and a beta of 0.06.

Analyst Upgrades and Downgrades

ZURA has been the subject of a number of analyst reports. Oppenheimer restated an "outperform" rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital dropped their price target on shares of Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a report on Wednesday, December 11th. HC Wainwright restated a "neutral" rating and issued a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Guggenheim reiterated a "buy" rating and set a $15.00 target price on shares of Zura Bio in a research report on Wednesday, March 26th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $15.00.

Institutional Investors Weigh In On Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE increased its stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 41,222 shares of the company's stock after purchasing an additional 9,966 shares during the quarter. Bank of America Corp DE owned 0.06% of Zura Bio worth $103,000 at the end of the most recent quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.